Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Jeschke M, Ludwig JM, Leyh C, Pabst KM, Weber M, Theysohn JM, Lange CM, Herrmann K, Schmidt HH, Jochheim LS. Jeschke M, et al. Cancers (Basel). 2023 Aug 26;15(17):4274. doi: 10.3390/cancers15174274. Cancers (Basel). 2023. PMID: 37686549 Free PMC article.
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.
de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Ben Khaled N, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. de Castro T, et al. Among authors: jeschke m. Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35251317 Free PMC article.
Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90Y Glass Microspheres.
Watanabe M, Grafe H, Theysohn J, Schaarschmidt B, Ludwig J, Jochheim L, Jeschke M, Schmidt H, Fendler WP, Moraitis A, Herrmann K, Pomykala KL, Weber M. Watanabe M, et al. Among authors: jeschke m. J Nucl Med. 2023 Jul;64(7):1102-1108. doi: 10.2967/jnumed.122.264996. Epub 2023 Jun 8. J Nucl Med. 2023. PMID: 37290792 Free article.
Frailty as a sequela of burn injury: a post hoc analysis of the "RE-ENERGIZE" multicenter randomized-controlled trial and the National Health Interview Survey.
Panayi AC, Heyland DK, Stoppe C, Jeschke MG, Knoedler S, Tapking C, Didzun O, Haug V, Bigdeli AK, Kneser U, Orgill DP, Hundeshagen G. Panayi AC, et al. Among authors: jeschke mg. Mil Med Res. 2024 Sep 12;11(1):63. doi: 10.1186/s40779-024-00568-x. Mil Med Res. 2024. PMID: 39267196 Free PMC article. Clinical Trial.
β-Adrenergic blockade attenuates adverse adipose tissue responses after burn.
Bieerkehazhi S, Abdullahi A, Khalaf F, Barayan D, de Brito Monteiro L, Samadi O, Rix G, Jeschke MG. Bieerkehazhi S, et al. Among authors: jeschke mg. J Mol Med (Berl). 2024 Oct;102(10):1245-1254. doi: 10.1007/s00109-024-02478-w. Epub 2024 Aug 15. J Mol Med (Berl). 2024. PMID: 39145814
Post-burn endocrine-immune dynamics and ageing considerations.
Khalaf F, Ricciuti Z, Barayan D, Wojtowicz-Piotrowski S, Jeschke MG. Khalaf F, et al. Among authors: jeschke mg. Nat Rev Endocrinol. 2024 Oct;20(10):567-568. doi: 10.1038/s41574-024-01018-3. Nat Rev Endocrinol. 2024. PMID: 38982289 No abstract available.
496 results